Aurora Spine Corporation (ASAPF)

Aurora Spine Corporation (ASAPF) — VMCI valuation read

Headline read on ASAPF: VMCI of 40/100 versus a Healthcare sector median of 50. The 10-point below-median position is what makes Aurora Spine Corporation a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on ASAPF: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on ASAPF: value (ASAPF trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -2.2x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

ASAPF rose 3.0% over the trailing 7 days, with a +2.1% read on a 30-day basis.